FDA approves Synjardy XR from Lilly, Boehringer Ingelheim

RIDGEFIELD, Conn. and INDIANAPOLIS — The Food and Drug Administration has approved Eli Lilly & Co.’s and Boehringer Ingelheim’s Synjardy XR (empagliflozin and metformin hydrochloride) extended-release tablets. The drug is indicated to improve blood sugar in adults with Type 2 diabetes when both empagliflozin and metformin can be taken. 

 

“Adults with Type 2 diabetes often take multiple medications, sometimes more than once a day, to manage their condition,” Boehringer Ingelheim president and CEO Paul Fonteyne said. “With Synjardy XR, the eighth FDA-approved treatment to emerge from our partnership with Lilly, adults with type 2 diabetes now have another convenient daily option to help them reach their glycemic goals, whether they are already being treated or are just at the beginning of their treatment.”